TESOFENSINE

Weight Loss & MetabolicResearch Only

Exceptionally strong clinical evidence with consistent 10%+ weight loss across multiple trials, but cardiovascular safety concerns have stalled development. The efficacy data rivals any weight loss compound ever tested in humans.

Obesity researchers and pharmaceutical companies investigating alternatives to GLP-1 receptor agonists, particularly those focused on central nervous system approaches to weight management.

FDA Status
Research Only

Since Feb 2026

Evidence
Strong
Studies

30 total, 11 human

What is TESOFENSINE?

Originally developed as a neurological treatment, this compound unexpectedly emerged as one of the most potent weight loss agents in clinical testing. Obesity researchers now focus almost exclusively on its metabolic effects after early trials showed dramatic results that caught the pharmaceutical industry's attention. The compound works through brain chemistry rather than hormonal pathways, setting it apart from newer diabetes medications repurposed for weight management.

The compound blocks transporters that normally clear three key brain chemicals—serotonin, norepinephrine, and dopamine—from synapses after they've delivered their signals. This creates a sustained elevation of all three neurotransmitters simultaneously, which suppresses hunger signals while potentially boosting energy expenditure and mood. Think of it as preventing your brain from 'turning off' the chemical signals that control appetite and motivation.

What the Research Shows

Robust clinical dataset with 11 human studies including multiple randomized controlled trials, though development halted due to blood pressure and heart rate increases in phase 2 testing.

Evidence from 26 human studies including 9 randomized controlled trials demonstrates that tesofensine produces approximately double the weight loss of sibutramine but is associated with increases in blood pressure and heart rate, with pharmacokinetic/pharmacodynamic modeling having predicted a negative outcome in a phase IIb Alzheimer's disease trial.

Notable Studies

Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease.

Hauser RA, Salin L, Juhel N et al. · Mov Disord (2007)

RCT · Phase 2 · n=2611 · 4 weeks

\[The effect of tesofensine on body weight and body composition in obese subjects--secondary publication\].

Nielsen AL, Larsen TM, Madsbad S et al. · Ugeskr Laeger (2009)

RCT · Phase 2 · n=2032 · 4 weeks

The effect of tesofensine on appetite sensations.

Gilbert JA, Gasteyger C, Raben A et al. · Obesity (Silver Spring) (2012)

RCT · Phase 2 · n=1582 · 4 weeks

Reported Benefits

Significant weight loss potential7 studies
Appetite suppression3 studies
Increased satiety2 studies
Potential cognitive benefits2 studies

Regulatory Status

Research OnlyEffective: Feb 2026

Last verified: Feb 2026

Related Peptides

This information is for research purposes only and does not constitute medical advice. Always consult a licensed physician before using any peptides.